Trial Profile
PET/MRI and plaque vulnerability A feasibility study of 18F-Flutemetamol in atherosclerosis.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Atherosclerosis
- Focus Diagnostic use
- 03 Nov 2020 Status changed from recruiting to discontinued.
- 20 Jan 2017 New trial record